Karolinska Institute to Use OmniCorder's Functional Medical Imaging System
Monday December 20, 10:10 am ET
BioScanIR System to Stage and Monitor Breast Cancer and Melanoma Therapies
BOHEMIA, N.Y.--(BUSINESS WIRE)--Dec. 20, 2004--OmniCorder Technologies, Inc. (OTCBB Symbol:OMCT - News) today announced the shipment of its BioScanIR® System to Karolinska Institute in Stockholm, Sweden. The system will be used in a number of studies including an assessment and grading of skin cancer, an evaluation of radiation therapy's impact on microcirculation within breast tissue, and an assessment of the effectiveness of peripheral vascular wound healing therapies. The team of researchers will be lead by Professor Anders Brahme, Director of the Division of Medical Radiation Physics and Research Center for Radiation Therapy. As part of a comprehensive strategy, the system has been specifically configured for cancer therapy management applications and is being deployed in a series of international studies to further validate its utility in patient management.
"The Karolinska Institute's pilot program is the third in a series of international installations that focus on cancer therapy monitoring applications," said Michael A. Davis, M.D., D.Sc., Chairman of the Executive Committee of OmniCorder's Board of Directors. "We believe our functional imaging technology will have a significant impact on the way superficial cancers and peripheral vascular disease are managed, and expect The Karolinska Institute's work will demonstrate this."
The BioScanIR® System:
The Company's BioScanIR System is a functional medical imaging modality that provides a fast, non-invasive, radiation free method for detecting and managing a wide variety of diseases that affect blood perfusion--such as cancer and vascular disease--by detecting minute changes in temperature based on the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense by NASA's Jet Propulsion Laboratory. The Company owns an exclusive, worldwide license to use the technology for biomedical applications.
OmniCorder has successfully used the BioScanIR System in a number of key medical markets, including: Breast Cancer Detection, Cancer Therapy Monitoring, Drug Discovery, Neurosurgery and Reconstructive Surgery. The System has the capacity to cost-effectively improve disease detection, enhance clinical decision making and improve therapy management in a vast number of medical applications.
About OmniCorder Technologies, Inc.:
OmniCorder Technologies Inc., headquartered in Bohemia, New York, is a leading developer of functional medical imaging applications using advanced infrared focal plane arrays. OmniCorder's imaging technology has utility for clinicians and researchers in drug discovery, disease detection and disease management applications.
OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting high-resolution infrared technology for biomedical applications.
About Karolinska Institute:
Founded in 1810, Karolinska Institute is one of Europe's largest medical universities and one of the best known clinical and biomedical research centers in the world. It is especially well known as the institute that awards the Nobel Prize in Physiology and Medicine. As Sweden's largest center for medical training and research, Karolinska accounts for 30 percent of the nation's medical training and 40 percent of its medical academic research. Karolinska Institute's mission is to improve the health of mankind through research, education and information. Early confirmation of Karolinska Institute's standing in the natural scientific field came in 1895, when Alfred Nobel appointed the Institute to select the Nobel Prize winner in Physiology and Medicine. Through this role the Institute has established a broad contact network within the medical scientific community. Over the years, five research workers from Karolinska Institute have been awarded the Nobel Prize in Physiology or Medicine.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact:
OmniCorder Technologies, Inc.
Anne Marie Fields, 212-292-5710
E-mail: afields@omnicorder.com
Source: OmniCorder Technologies, Inc. |
